Pancreatic Cancer

CYNVILOQâ„¢ in ASCO 2013 Pancreatic Ca. Sorrento Therapeutics, Inc

IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO). 

Phase II Clinical Trial of Paclitaxel Loaded Polymeric

Purpose: To determine in patients, with locally advanced or metastatic pancreatic cancer (APC), efficacy and safety of treatment with intravenous paclitaxel loaded polymeric micelle (GPM). Patients and methods: This was a multicenter, open-label Phase II study. Patients with APC, ECOG performance status ≤ 2, no prior chemotherapy and adequate organ function were treated with 3-hour GPM infusions every 3 weeks. Initial patients were treated with 435 mg/m2 (n = 11).

Phase II trial of GPM with pancreatic cancer

Pancreatic cancer remains a chemo-resistant disease (1).Gemcitabine has been an acceptable standard for more than a decade. The benefit of single-agent gemcitabine in advanced

Brand Name: PAXUS™ PM (South East Asia), GENEXOL® PM (Korea & other territories)